HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.01201005v1 1/2/221    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Müller, D. N. Articles by Luft, F. C. Search for Related Content PubMed PubMed Citation Articles by Müller, D. N. Articles by Luft, F. C. Related Collections Related Article

Direct Renin Inhibition with Aliskiren in Hypertension and Target Organ Damage

Medical Faculty of the Charité, Max Delbrück Center for Molecular Medicine, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany

Address correspondence to: Dr. Friedrich C. Luft, Franz Volhard Clinic, Wiltberg Strasse 50, Berlin 13125, Germany. Phone: +49-30-9417-2202; Fax: +49-30-9417-2206; E-mail: luft{at}fvk-berlin.de

The Joint National Committee and the World Health Organization are in agreement that hypertension in most patients who are treated is controlled inadequately and that rates of cardiovascular morbidity remain high. Additional pharmacologic treatments could ameliorate this situation. The renin-angiotensin-aldosterone system has been a highly successful pharmacologic target, as the system is strongly implicated in the development of hypertension-related target organ damage. However, compensatory increases in plasma renin levels that lead to adjustments in angiotensin production and conversion present limitations for existing renin-angiotensin-aldosterone system inhibitors. A once-daily, orally effective, small-molecule renin inhibitor, aliskiren, is now available to address angiotensin production directly at its rate-limiting step. Studies in humans attest to an effective BP-lowering effect, a side effect profile no different from AT₁ receptor blockers, and the option of combination therapies. A novel animal model of high human renin hypertension in the rat attest to target organ protection. Because angiotensin receptor blockade, angiotensin-converting enzyme inhibition, calcium channel blockade, and diuretic therapy all lead to sharp increases in plasma renin activity, aliskiren offers a novel circumvention.

Related Article

Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Type 1 Receptor Antagonist Therapy Is Associated with Prolonged Patient and Graft Survival after Renal Transplantation

Georg Heinze, Christa Mitterbauer, Heinz Regele, Reinhard Kramar, Wolfgang C. Winkelmayer, Gary C. Curhan, and Rainer Oberbauer
J. Am. Soc. Nephrol. 2006 17: 889-899. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				N. D.L. Fisher, A.H. Jan Danser, J. Nussberger, W. P. Dole, and N. K. Hollenberg Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans Circulation, June 24, 2008; 117(25): 3199 - 3205. [Abstract] [Full Text] [PDF]

				A. J. Danser and G. Nguyen Spotlight on Renin: The Renin Academy Summit: advancing the understanding of renin science Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 119 - 123. [PDF]

				S. Feldt, U. Maschke, R. Dechend, F. C. Luft, and D. N. Muller The Putative (Pro)renin Receptor Blocker HRP Fails to Prevent (Pro)renin Signaling J. Am. Soc. Nephrol., April 1, 2008; 19(4): 743 - 748. [Abstract] [Full Text] [PDF]

				M. J Brown Direct renin inhibition -- a new way of targeting the renin system Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2_suppl): S7 - S11. [Abstract] [PDF]